Firm Submitted New Heart Attack Drug Application
The FDA is now reviewing zalunfiban, an injectable medication designed for use during heart attacks.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Do you trust that new drug breakthroughs will improve emergency heart care in your area?
On June 24, 2026, CeleCor Therapeutics submitted the final section of its New Drug Application to the Food and Drug Administration for zalunfiban. This medication is intended to treat patients experiencing ST-segment elevation heart attacks.
Why it matters
The submission follows the FDA granting zalunfiban Fast Track status and a Rolling Review process, which allows regulators to begin evaluations early. This regulatory approach aims to potentially shorten the timeline for making new treatments accessible in clinical settings.
Phase 3 study results for zalunfiban were presented in November 2025 and subsequently published in The New England Journal of Medicine Evidence. The findings demonstrate the efficacy and safety profile of the drug in the trial population.
The players
CeleCor Therapeutics
A biopharmaceutical company based in Del Mar, California, focused on developing treatments for cardiovascular conditions.
Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of new medical therapies in the United States.
Michael Moye
The recently appointed Chief Commercial Officer of CeleCor Therapeutics tasked with leading commercial strategy.
The details
Zalunfiban is designed for subcutaneous injection, allowing for administration at the first point of medical contact during a heart attack. By enabling treatment as soon as a patient encounters medical professionals, the drug aims to intervene rapidly during the acute phase of an ST-segment elevation event. CeleCor Therapeutics has also appointed a Chief Commercial Officer to oversee the strategy and operations necessary to support the drug's potential market entry.
Timeline
November 2025: Phase 3 results were presented at the American Heart Association Scientific Sessions.
January 2026: Zalunfiban was granted Rolling Review by the FDA.
June 24, 2026: CeleCor submitted the final New Drug Application section to the FDA.
Health Landscape
The use of Rolling Review reflects a broader trend in cardiac care where regulatory pathways are optimized to speed the delivery of time-sensitive interventions. This application follows a shift toward prioritizing early-contact treatments for acute cardiac events.
If you or a loved one have a history of heart conditions, this development represents a potential new treatment option currently under regulatory review. It is worth discussing with your doctor how advancements in emergency cardiac care, such as injectable therapies, may eventually change standard protocols.
The takeaway
The pursuit of faster regulatory pathways for cardiac drugs reflects the vital importance of rapid intervention during heart attacks. Patients should continue to prioritize following existing emergency care protocols established by their medical teams.
Further reading
For more information on current treatment standards, visit our section on Heart Disease.
Source note: This article includes information reported by Drugs.
Live Poll
Do you trust that new drug breakthroughs will improve emergency heart care in your area?
